D
Ascendis Pharma A/S ASND
$168.84 $15.8610.37%
Recommendation
Sell
Prev Close
$168.84
Volume
46
Avg Vol (90D)
478,038
Market Cap
$10.10B
Dividend & Yield
--
52-Week Range
$111.09 - $169.37
P/E (TTM)
--
EPS (TTM)
-$7.14
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Good
Efficiency Index
Very Weak
Solvency Index
Weak
Total Return Index
Fair
Volatility Index
Weak
Dividend Index
--
Headlines
Ascendis Pharma A/S (ASND, $168.84) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 17, 2025
3/18/2025 - Tickeron - Stocks
Ascendis Pharma A/S (ASND, $152.98) Stochastic Oscillator left the overbought zone on March 14, 2025
3/15/2025 - Tickeron - Stocks
Ascendis Pharma A/S (ASND, $150.31) Stochastic Oscillator left the oversold zone on March 12, 2025
3/13/2025 - Tickeron - Stocks
Optimistic Investors Push Ascendis Pharma A/S (NASDAQ:ASND) Shares Up 26% But Growth Is Lacking
3/13/2025 - Simply Wall St
Victory Capital Management Inc. Sells 2,505 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
3/12/2025 - MarketBeat
Ascendis Pharma A/S (ASND, $138.18) Stochastic Oscillator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
Ascendis Pharma A/S (ASND, $138.18) Stochastic Oscillator left the oversold zone on March 10, 2025
3/11/2025 - Tickeron - Stocks
Ascendis Pharma A/S (ASND, $145.74) price may climb as it broke lower Bollinger Band on Mar 07, 2025
3/8/2025 - Tickeron - Stocks
Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Candriam S.C.A.
3/7/2025 - MarketBeat
12,528 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by Proficio Capital Partners LLC
3/7/2025 - MarketBeat
Candriam S.C.A. Has $38.57 Million Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
3/6/2025 - Ticker Report
Ascendis Pharma A/S (ASND, $151.93) RSI Indicator left the overbought zone on March 03, 2025
3/4/2025 - Tickeron - Stocks
Ascendis Pharma A/S (NASDAQ:ASND) Sets New 1-Year High - Here's Why
3/2/2025 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Position Reduced by Henry James International Management Inc.
3/1/2025 - Ticker Report
Ascendis Pharma A/S (NASDAQ:ASND) Given Average Rating of "Moderate Buy" by Analysts
2/28/2025 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Handelsbanken Fonder AB
2/26/2025 - MarketBeat
Cantor Fitzgerald Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) Stock
2/25/2025 - Ticker Report
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $200.00 at Cantor Fitzgerald
2/25/2025 - MarketBeat
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
2/24/2025 - Globe Newswire
New York State Common Retirement Fund Acquires 25,164 Shares of Ascendis Pharma A/S (NASDAQ:ASND)
2/21/2025 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $260.00 at Evercore ISI
2/19/2025 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Given New $260.00 Price Target at Evercore ISI
2/18/2025 - Ticker Report
Rice Hall James & Associates LLC Has $22.56 Million Stock Holdings in Ascendis Pharma A/S (NASDAQ:ASND)
2/18/2025 - MarketBeat
Q1 EPS Estimates for Ascendis Pharma A/S Lowered by Wedbush
2/17/2025 - MarketBeat
Ascendis Pharma A/S (NASDAQ:ASND) Yearly Results: Here's What Analysts Are Forecasting For This Year
2/15/2025 - Simply Wall St
Income Statement
Total Revenue (TTM)
$391.82M
EBITDA (TTM)
-$287.02M
EBIT (TTM)
-$302.73M
Net Income (TTM)
-$410.04M
Balance Sheet
Total Assets (Q)
$1.22B
Total Debt (Q)
$886.86M
Total Liabilities (Q)
$1.33B
Book Value Per Share (Q)
-$1.83
Cash Flow
Cash from Operations (TTM)
-$330.90M
Cash from Investing (TTM)
$7.46M
Cash from Financing (TTM)
$487.84M
Net Change in Cash (TTM)
$188.63M
Filings
Filing Date
Wednesday, February 12, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Beginning of May (est)
Price History
Loading...
Beta
0.90
7-Day Total Return
15.85%
30-Day Total Return
34.97%
60-Day Total Return
20.34%
90-Day Total Return
34.25%
Year to Date Total Return
22.35%
1-Year Total Return
14.81%
2-Year Total Return
53.77%
3-Year Total Return
43.77%
5-Year Total Return
71.59%
52-week Low
Sep 12, 2024 - $111.09
52-week High
Mar 17, 2025 - $169.37
Valuation
Market Cap
$10.10B - Large Cap
Enterprise Value
$10.41B
Price/Sales (TTM)
25.76
Price/Book (Q)
-92.33
Dividends and Shares
Shares Outstanding
59.79M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
ascendispharma.com
Phone Number
45 70 22 22 44
Address
Tuborg Boulevard 12
Hellerup, 2900
Country
Denmark
Year Founded
2006
Business Description
Sector
--
Industry
--
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The... more
NASDAQ 03/17/2025 4:00PM Eastern Quotes delayed
Weiss Ratings